H. Miles Prince
Melbourne haematologist who led ALCANZA, the trial that showed brentuximab vedotin beats standard treatment for CD30-expressing cutaneous T-cell lymphoma.
Overview
Miles Prince is a haematologist at the Peter MacCallum Cancer Centre and Epworth Healthcare in Melbourne. He was first author of the 2017 Lancet report of ALCANZA, the international phase 3 trial in which brentuximab vedotin produced more lasting responses than physician's choice of methotrexate or bexarotene in previously treated CD30-positive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma, leading to the drug's approval in this setting.
Similar pages
not linked directly; found by shared links- PersonYoun H. Kim
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tags lymphoma, trialist.
- PersonJohn P. Leonard
Shares the tags lymphoma, trialist.
- PersonGilles Salles
Shares the tags lymphoma, trialist.
- PersonPhilippe Armand
Shares the tags lymphoma, trialist.
- PersonCaron A. Jacobson
Shares the tags lymphoma, trialist.
- TreatmentMethoxsalen (extracorporeal photopheresis)
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
- TechnologyTotal skin electron beam therapy
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
- TreatmentBexarotene
Shares ALCANZA, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).